Rani Therapeutics (RANI) Competitors $0.46 +0.02 (+4.02%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$0.44 -0.02 (-3.52%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. CRBP, HLVX, TCRX, CHRS, CLYM, ZNTL, OKYO, CLLS, CRDL, and VXRTShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Corbus Pharmaceuticals (CRBP), HilleVax (HLVX), TScan Therapeutics (TCRX), Coherus Oncology (CHRS), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), OKYO Pharma (OKYO), Cellectis (CLLS), Cardiol Therapeutics (CRDL), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Corbus Pharmaceuticals HilleVax TScan Therapeutics Coherus Oncology Climb Bio Zentalis Pharmaceuticals OKYO Pharma Cellectis Cardiol Therapeutics Vaxart Corbus Pharmaceuticals (NASDAQ:CRBP) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Is CRBP or RANI more profitable? Corbus Pharmaceuticals' return on equity of -36.87% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -36.87% -32.87% Rani Therapeutics N/A -1,258.76%-80.52% Does the media prefer CRBP or RANI? In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Corbus Pharmaceuticals and 1 mentions for Rani Therapeutics. Corbus Pharmaceuticals' average media sentiment score of 0.55 beat Rani Therapeutics' score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CRBP or RANI? Corbus Pharmaceuticals currently has a consensus price target of $50.88, indicating a potential upside of 478.78%. Rani Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,511.72%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, CRBP or RANI? Rani Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$40.21M-$4.22-2.08Rani Therapeutics$1.03M27.92-$30.02M-$0.99-0.46 Which has more volatility & risk, CRBP or RANI? Corbus Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRBP or RANI? 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCorbus Pharmaceuticals beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.65M$2.99B$5.57B$9.42BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-0.4621.2528.0920.08Price / Sales27.92253.33403.9184.07Price / CashN/A41.9636.1958.45Price / Book7.588.198.615.83Net Income-$30.02M-$55.10M$3.24B$258.27M7 Day Performance9.14%5.56%3.53%2.69%1 Month Performance-8.41%18.19%10.99%12.91%1 Year Performance-84.04%7.32%35.43%21.81% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics1.7928 of 5 stars$0.46+4.0%$7.33+1,511.7%-85.0%$27.65M$1.03M-0.46110Gap UpCRBPCorbus Pharmaceuticals4.7844 of 5 stars$8.56+0.7%$50.88+494.3%-84.8%$104.01MN/A-2.0340Positive NewsHLVXHilleVax1.7464 of 5 stars$2.05-0.5%$2.00-2.4%+8.2%$103.29MN/A-0.9520TCRXTScan Therapeutics3.2562 of 5 stars$1.83+0.5%$7.80+326.2%-74.3%$103M$2.82M-1.68100CHRSCoherus Oncology3.4974 of 5 stars$0.89+0.7%$4.68+428.1%-41.0%$102.11M$266.96M-0.78330CLYMClimb Bio2.6105 of 5 stars$1.41-6.6%$9.00+538.3%N/A$102.04MN/A-0.599Positive NewsZNTLZentalis Pharmaceuticals1.7144 of 5 stars$1.39-1.4%$8.37+501.9%-64.1%$101.45M$67.43M-0.44160Positive NewsOKYOOKYO Pharma2.9626 of 5 stars$2.82-5.7%$7.00+148.2%+70.1%$101.17MN/A0.007CLLSCellectis2.7747 of 5 stars$1.83+0.5%$4.00+118.6%+12.6%$101.16M$49.22M-2.13290Gap UpCRDLCardiol Therapeutics2.2885 of 5 stars$1.22+2.5%$8.00+555.7%-39.2%$98.35MN/A-3.5920Positive NewsVXRTVaxart3.4175 of 5 stars$0.42-3.6%$3.00+606.0%-39.1%$97.27M$47.40M-1.57120Positive News Related Companies and Tools Related Companies CRBP Alternatives HLVX Alternatives TCRX Alternatives CHRS Alternatives CLYM Alternatives ZNTL Alternatives OKYO Alternatives CLLS Alternatives CRDL Alternatives VXRT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
